Metabolic & incretin
Incretin biology, glucose regulation, appetite signaling, and metabolic medicines in development or use.
Questions
What does the Metabolic and incretin category cover?
The sampled monographs span approved GLP-1 medicine semaglutide, dual GIP and GLP-1 agonist tirzepatide, investigational triple agonist retatrutide, investigational amylin analogue cagrilintide, and approved amylin analogue pramlintide. The category reflects overlapping metabolic biology, not interchangeability.
Are all sampled Metabolic and incretin entries approved medicines?
No. Semaglutide, tirzepatide, and pramlintide have documented FDA approvals for specified indications. Retatrutide and cagrilintide remained investigational at the monographs' review dates. Investigational status means no established or recommended human dose exists.
Do semaglutide and tirzepatide have the same mechanism?
No. Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors. Both are approved medicines, but their indications, evidence, and labeled regimens are product-specific and should be checked in their individual monographs.
What does the retatrutide record show about development status?
Retatrutide is an investigational GIP, GLP-1, and glucagon receptor agonist with reported phase 2 and phase 3 findings. The monograph identified no marketing authorization in the major regulator databases reviewed. Trial results do not by themselves establish approval or a recommended human dose.
Why should cagrilintide not be treated as pramlintide?
Both relate to amylin signaling, but cagrilintide is an investigational acylated analogue in phase 3 development, whereas pramlintide is an approved adjunct for specified diabetes care. Their molecules, evidence bases, regulatory statuses, and studied or labeled regimens are distinct.
Join the atlas. Get the evidence updates.
Receive concise notes when peptide evidence, status, or source records change.